Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      AstraZeneca Brilinta Phase III trial meets primary goal

      AstraZeneca Brilinta Phase III trial meets primary goal

      Farhat Nasim2 March 2019 9:00 AM IST
      WILMINGTON: British drugmaker AstraZeneca Plc recently announced that the Phase III THEMIS trial met its primary endpoint which demonstrated that...
      J&J passes asbestos test, allowed to make baby powder in India

      J&J passes asbestos test, allowed to make baby powder in India

      Farhat Nasim1 March 2019 2:28 PM IST
      NEW DELHI: In a major relief to Johnson & Johnson(J&J), no asbestos was found in the baby powder manufactured in Baddi and Mulund plants. The...
      Torrent Pharma recalls around 2.30 lakh bottles of high BP drugs from US

      Torrent Pharma recalls around 2.30 lakh bottles of high BP drugs from US

      Farhat Nasim1 March 2019 1:06 PM IST
      The company is also recalling 18,852 bottles of Losartan Potassium and Hydrochlorothiazide tablets in the strength of 100 mg and 12.5 mg, and 18,780...
      Lupin receives USFDA nod to Azacitidine for Injection

      Lupin receives USFDA nod to Azacitidine for Injection

      Farhat Nasim1 March 2019 9:30 AM IST
      Lupin's Azacitidine for Injection, 100 mg Single-Dose Vial is a generic version of Celgene Corporation's Vidaza.Mumbai: Mumbai-based drugmaker, Lupin...
      AstraZeneca Lynparza succeeds in pancreatic cancer study

      AstraZeneca Lynparza succeeds in pancreatic cancer study

      Farhat Nasim1 March 2019 9:15 AM IST
      Lynparza, which is currently being used as a treatment for ovarian and breast cancers, showed it was better at delaying the rare pancreatic cancer...
      Aurobindo Pharma facility manufacturing Sterile Injections fails to establish sterility, says USFDA

      Aurobindo Pharma facility manufacturing Sterile Injections fails to establish sterility, says USFDA

      Farhat Nasim28 Feb 2019 5:49 PM IST
      According to the FDA report unveiled recently, procedures designed to prevent microbiological contamination of drug products purporting to be sterile...
      Drug exporters wary of tension between India, Pakistan post Pulwama attack

      Drug exporters wary of tension between India, Pakistan post Pulwama attack

      Farhat Nasim28 Feb 2019 9:15 AM IST
      The Indian pharmaceutical companies exports over USD 140 million to Pakistan with 50 per cent active pharmaceutical ingredients (API).HYDERABAD: In...
      Merck launches cutting edge fertility technologies in India

      Merck launches cutting edge fertility technologies in India

      Farhat Nasim28 Feb 2019 9:05 AM IST
      The introduction of cutting-edge fertility technology complements Merck portfolio and promises to decrease manual labour, increases precision and thus...
      Boehringer Ingelheim, GNA Biosolutions partners on emergency diagnostics development

      Boehringer Ingelheim, GNA Biosolutions partners on emergency diagnostics development

      Farhat Nasim28 Feb 2019 9:00 AM IST
      The Boehringer and GNA Biosolutions collaboration further emphasises the role of GNA Biosolutions in the rapidly developing field of extra-laboratory...
      Lupin launches Minocycline Hydrochloride extended release tablets in US

      Lupin launches Minocycline Hydrochloride extended release tablets in US

      Farhat Nasim27 Feb 2019 9:40 AM IST
      The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United...
      Shilpa Medicare gets USFDA nod for Gemcitabine to treat types of cancer

      Shilpa Medicare gets USFDA nod for Gemcitabine to treat types of cancer

      Farhat Nasim27 Feb 2019 9:30 AM IST
      The company has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection...
      Fortis Healthcare petitions SEBI seeking arrest of Singh brothers

      Fortis Healthcare petitions SEBI seeking arrest of Singh brothers

      Farhat Nasim26 Feb 2019 11:02 AM IST
      On January 18, 2019, the SEBI deadline for notices to pay back money to Fortis expired and on February 13, 2019, a petition was filed by Fortis with...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok